IL139286A - Polyol-ifn-beta conjugates, their preparation and use - Google Patents

Polyol-ifn-beta conjugates, their preparation and use

Info

Publication number
IL139286A
IL139286A IL13928699A IL13928699A IL139286A IL 139286 A IL139286 A IL 139286A IL 13928699 A IL13928699 A IL 13928699A IL 13928699 A IL13928699 A IL 13928699A IL 139286 A IL139286 A IL 139286A
Authority
IL
Israel
Prior art keywords
ifn
beta
peg
polyol
preparation
Prior art date
Application number
IL13928699A
Other languages
English (en)
Other versions
IL139286A0 (en
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of IL139286A0 publication Critical patent/IL139286A0/xx
Publication of IL139286A publication Critical patent/IL139286A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL13928699A 1998-04-28 1999-04-28 Polyol-ifn-beta conjugates, their preparation and use IL139286A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8333998P 1998-04-28 1998-04-28
PCT/US1999/009161 WO1999055377A2 (en) 1998-04-28 1999-04-28 Polyol-ifn-beta conjugates

Publications (2)

Publication Number Publication Date
IL139286A0 IL139286A0 (en) 2001-11-25
IL139286A true IL139286A (en) 2005-12-18

Family

ID=22177687

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13928699A IL139286A (en) 1998-04-28 1999-04-28 Polyol-ifn-beta conjugates, their preparation and use

Country Status (31)

Country Link
US (3) US6638500B1 (sl)
EP (2) EP1421956B1 (sl)
JP (2) JP4574007B2 (sl)
KR (1) KR100622796B1 (sl)
CN (2) CN100335503C (sl)
AR (1) AR020070A1 (sl)
AT (2) ATE365563T1 (sl)
AU (1) AU762621B2 (sl)
BG (2) BG64694B1 (sl)
BR (1) BR9910023A (sl)
CA (2) CA2565375A1 (sl)
CY (1) CY1108022T1 (sl)
CZ (2) CZ298597B6 (sl)
DE (2) DE69920002T2 (sl)
DK (2) DK1075281T3 (sl)
EA (2) EA003789B1 (sl)
EE (1) EE05214B1 (sl)
ES (2) ES2224649T3 (sl)
HK (2) HK1038194A1 (sl)
HU (1) HUP0300548A3 (sl)
IL (1) IL139286A (sl)
NO (2) NO329749B1 (sl)
NZ (1) NZ507456A (sl)
PL (2) PL196533B1 (sl)
PT (2) PT1421956E (sl)
SI (2) SI1075281T1 (sl)
SK (2) SK286217B6 (sl)
TR (2) TR200101751T2 (sl)
TW (2) TWI266800B (sl)
UA (2) UA79430C2 (sl)
WO (1) WO1999055377A2 (sl)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
IL142282A0 (en) * 1998-10-16 2002-03-10 Biogen Inc Compositions containing polymer conjugates of interferon-beta-1a
IL142350A0 (en) 1998-10-16 2002-03-10 Biogen Inc Interferon-beta fusion proteins and pharmaceutical compositions containing the same
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
ATE340592T1 (de) * 1999-04-23 2006-10-15 Alza Corp Konjugate enthaltend eine spaltbare bindung zur anwendung in einem liposom
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7431921B2 (en) 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
TR200101086A3 (sl) * 1999-10-15 2001-08-21
US7691367B2 (en) 1999-12-24 2010-04-06 Kyowa Hakko Kirin Co., Ltd. Branched polyalkylene glycols
CA2395713C (en) 2000-01-10 2012-04-10 Torben Lauesgaard Nissen G-csf conjugates
CN100488562C (zh) 2000-02-11 2009-05-20 拜耳医药保健有限公司 凝血因子VⅡ或VⅡa样分子
WO2002060978A1 (fr) 2001-01-30 2002-08-08 Kyowa Hakko Kogyo Co., Ltd. Polyalkylene glycols ramifies
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
EP2080771A3 (en) 2001-02-27 2010-01-06 Maxygen Aps New interferon beta-like molecules
BR0211071A (pt) 2001-07-11 2004-12-21 Maxygen Holdings Ltd Conjugado polipeptìdico apresentando atividade de g-csf, método para preparar um conjugado de g-csf, composição, método para tratar um mamìfero sofrendo de um nìvel neutrofìlico insuficiente, e, uso do conjugado polipeptìdico
WO2003061577A2 (en) 2002-01-18 2003-07-31 Biogen Idec Ma Inc. Polyalkylene glycol with moiety for conjugating biologically active compound
TWI334785B (en) 2002-06-03 2010-12-21 Serono Lab Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
WO2004020468A2 (en) * 2002-08-28 2004-03-11 Maxygen Aps Interferon beta-like molecules for treatment of cancer
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
TWI364295B (en) 2002-12-26 2012-05-21 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
EA008866B1 (ru) * 2002-12-26 2007-08-31 Маунтин Вью Фамэсьютикэлс, Инк. ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
US7771996B2 (en) 2003-03-20 2010-08-10 Bayer Healthcare Llc FVII or FVIIa variants
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
EP2641611A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
JP4896745B2 (ja) * 2004-02-02 2012-03-14 アンブレツクス・インコーポレイテツド 修飾されたヒトインターフェロンポリペプチドおよびこれらの使用
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
UA88300C2 (ru) 2004-05-17 2009-10-12 Эйрес Трейдинг С.А. Гидрогелевые композиции, которые содержат интерферон
US7731948B2 (en) 2004-06-01 2010-06-08 Ares Trading S.A. Stabilized interferon liquid formulations
EA012281B1 (ru) 2004-06-01 2009-08-28 Арес Трейдинг С.А. Способ стабилизации белков
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
MX2007007471A (es) * 2004-12-21 2007-07-20 Nektar Therapeutics Al Corp Reactivos de tiol polimericos estabilizados.
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
CN103690936A (zh) 2004-12-22 2014-04-02 Ambrx公司 经修饰的人类生长激素
EP2360170A3 (en) 2005-06-17 2012-03-28 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered proteins comprinsing at least one non-native cysteine
US20070092482A1 (en) * 2005-08-04 2007-04-26 Bossard Mary J Conjugates of a G-CSF moiety and a polymer
AU2005335900B2 (en) 2005-08-26 2012-03-29 Ares Trading S.A. Process for the preparation of glycosylated interferon beta
WO2007025991A2 (en) 2005-09-01 2007-03-08 Ares Trading S.A. Treatment of optic neuritis
US20070238656A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Functionalized poly(ethylene glycol)
WO2007130453A2 (en) * 2006-05-02 2007-11-15 Allozyne, Inc. Non-natural amino acid substituted polypeptides
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
CA2653154A1 (en) 2006-05-24 2007-11-29 Novo Nordisk Health Care Ag Prolonged fix analogues and derivatives
WO2007135172A2 (en) 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis
JP2010525821A (ja) 2007-05-02 2010-07-29 アンブルックス，インコーポレイテッド 修飾ＩＦＮβポリペプチドおよびこれらの使用
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
ES2387236T3 (es) * 2007-12-20 2012-09-18 Merck Serono S.A. Formulaciones de interferón beta pegilado
EP2247743B1 (en) 2008-02-08 2016-04-06 Ambrx, Inc. Modified leptin polypeptides and their uses
CN101525381B (zh) * 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 一种重组复合干扰素及其表达载体的构建和表达
US20100112660A1 (en) * 2008-05-30 2010-05-06 Barofold, Inc. Method for Derivatization of Proteins Using Hydrostatic Pressure
US20110124614A1 (en) * 2008-10-25 2011-05-26 Halina Offner Methods And Compositions For The Treatment of Autoimmune Disorders
DE102009032179A1 (de) * 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
ES2365343B1 (es) 2009-11-19 2012-07-10 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de cd98 como marcador de receptividad endometrial.
EP2536753B1 (en) 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
WO2011143274A1 (en) 2010-05-10 2011-11-17 Perseid Therapeutics Polypeptide inhibitors of vla4
WO2012007324A2 (en) 2010-07-15 2012-01-19 Novo Nordisk A/S Stabilized factor viii variants
CN104788557A (zh) 2010-09-15 2015-07-22 诺沃—诺迪斯克有限公司 具有减少的细胞摄取的因子viii变体
JP2014506889A (ja) * 2011-02-18 2014-03-20 ステムディーアール インク． Ｓｉｒｔ１発現誘導物質を含む敗血症または敗血症性ショックの予防または治療用組成物
WO2013004607A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
JP6153470B2 (ja) * 2011-10-01 2017-06-28 株式会社糖鎖工学研究所 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物
MX366864B (es) 2012-02-27 2019-07-26 Amunix Operating Inc Composiciones de conjugados de xten y métodos para realizarlas.
AU2013226944B2 (en) 2012-02-29 2017-03-23 Toray Industries, Inc. Inhibitory agent for body cavity fluid accumulation
KR102186063B1 (ko) 2013-03-29 2020-12-03 가부시키가이샤 도우사 고가쿠 겐큐쇼 시알릴화 당쇄가 부가된 폴리펩티드
WO2016013697A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 인터페론-베타 변이체의 폴리에틸렌글리콜 배합체
KR101671501B1 (ko) * 2014-07-24 2016-11-03 에이비온 주식회사 페길화된 인터페론-베타 변이체
SI3183264T1 (sl) 2014-08-19 2021-03-31 Biogen Ma Inc. Metoda pegilacije
CN115919996A (zh) 2015-05-01 2023-04-07 雅利斯塔制药公司 用于治疗眼科疾病的脂联素拟肽
UA124830C2 (uk) * 2015-06-19 2021-12-01 Ейсай Р&Д Менеджмент Ко., Лтд. Cys80-кон'юговані імуноглобуліни
WO2018195006A1 (en) * 2017-04-17 2018-10-25 The Regents Of The University Of Colorado, A Body Corporate Optimization of enzyme replacement therapy for treatment of homocystinuria
CA3124682A1 (en) 2019-01-28 2020-08-06 Toray Industries, Inc. Polyethylene glycol-modified form of hepatocyte growth factor or active fragment thereof
WO2020158690A1 (ja) 2019-01-28 2020-08-06 東レ株式会社 肝細胞増殖因子又はその活性断片のポリエチレングリコール修飾体

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
DE3676670D1 (de) * 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US5208344A (en) * 1987-07-31 1993-05-04 American Home Products Corporation Naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
HUT75533A (en) 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
EE9600121A (et) * 1994-03-31 1997-04-15 Amgen Inc. Megakarüotsüütide kasvu ja diferentseerumist stimuleerivad kompositsioonid ja meetodid
MX9605717A (es) * 1994-05-18 1998-05-31 Inhale Therapeutic Syst Metodos y composiciones para la formulacion de polvo seco de interferones.
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
KR0176625B1 (ko) 1996-11-05 1999-04-01 삼성전자주식회사 적외선 물체검출장치
ATE200030T1 (de) * 1997-01-29 2001-04-15 Polymasc Pharmaceuticals Plc Pegylationsverfahren
DE69838552T2 (de) * 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates

Also Published As

Publication number Publication date
SK286654B6 (sk) 2009-03-05
TR200003161T2 (tr) 2001-01-22
CA2565375A1 (en) 1999-11-04
NZ507456A (en) 2003-10-31
CA2330451A1 (en) 1999-11-04
PT1421956E (pt) 2007-07-13
US7700314B2 (en) 2010-04-20
BR9910023A (pt) 2000-12-26
DE69936409D1 (de) 2007-08-09
HUP0300548A3 (en) 2005-07-28
AU762621B2 (en) 2003-07-03
JP4574007B2 (ja) 2010-11-04
NO20005337L (no) 2000-12-28
DK1075281T3 (da) 2005-01-03
BG65046B1 (bg) 2007-01-31
PL344490A1 (en) 2001-11-05
EP1421956B1 (en) 2007-06-27
WO1999055377A2 (en) 1999-11-04
JP2002512983A (ja) 2002-05-08
PT1075281E (pt) 2004-11-30
ES2224649T3 (es) 2005-03-01
CN100335503C (zh) 2007-09-05
WO1999055377A9 (en) 2000-03-02
US7357925B2 (en) 2008-04-15
NO329749B1 (no) 2010-12-13
TWI232882B (en) 2005-05-21
US20040043002A1 (en) 2004-03-04
SI1075281T1 (sl) 2005-02-28
KR100622796B1 (ko) 2006-09-13
SK16222000A3 (sk) 2001-04-09
HK1076115A1 (en) 2006-01-06
HK1038194A1 (en) 2002-03-08
PL196533B1 (pl) 2008-01-31
CN1302209A (zh) 2001-07-04
SI1421956T1 (sl) 2007-10-31
DE69920002D1 (de) 2004-10-14
EE05214B1 (et) 2009-10-15
EP1075281B1 (en) 2004-09-08
IL139286A0 (en) 2001-11-25
CN1187094C (zh) 2005-02-02
PL193352B1 (pl) 2007-02-28
EA005495B1 (ru) 2005-02-24
CN1637020A (zh) 2005-07-13
AU3767499A (en) 1999-11-16
UA79430C2 (en) 2007-06-25
ATE275422T1 (de) 2004-09-15
BG64694B1 (bg) 2005-12-30
NO332224B1 (no) 2012-07-30
AR020070A1 (es) 2002-04-10
CZ20003995A3 (en) 2001-06-13
TWI266800B (en) 2006-11-21
HUP0300548A2 (hu) 2003-06-28
CY1108022T1 (el) 2013-09-04
NO20100324L (no) 2000-12-28
DE69920002T2 (de) 2005-09-22
CZ298579B6 (cs) 2007-11-14
DE69936409T2 (de) 2008-04-17
ATE365563T1 (de) 2007-07-15
TR200101751T2 (tr) 2002-05-21
CZ298597B6 (cs) 2007-11-21
DK1421956T3 (da) 2007-10-01
KR20010071158A (ko) 2001-07-28
NO20005337D0 (no) 2000-10-23
EE200000614A (et) 2002-04-15
EA200001111A1 (ru) 2001-04-23
EP1075281A2 (en) 2001-02-14
WO1999055377A3 (en) 1999-12-29
US6638500B1 (en) 2003-10-28
US20070141620A1 (en) 2007-06-21
UA66857C2 (uk) 2004-06-15
EA200300382A1 (ru) 2005-02-24
BG104871A (en) 2001-07-31
ES2285286T3 (es) 2007-11-16
JP2010184929A (ja) 2010-08-26
EP1421956A1 (en) 2004-05-26
EA003789B1 (ru) 2003-10-30
BG109291A (en) 2006-04-28
SK286217B6 (sk) 2008-05-06

Similar Documents

Publication Publication Date Title
IL139286A (en) Polyol-ifn-beta conjugates, their preparation and use
WO2006004959A3 (en) Pegylated interferon alpha-1b
CA2158054A1 (en) Conjugates of proteins and bifunctional ligands
CA2345027A1 (en) Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
WO2003022210A3 (en) Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
CA2312004A1 (en) Site-specific preparation of polyethylene glycol-grf conjugates
DE69835201D1 (en) Neoglycoproteine
UA103758C2 (ru) Конъюгаты олигомеров инсулина, их композиции и применение
DE69925830D1 (de) Peg-lhrh analog konjugate
IL94167A0 (en) Antibody delivery system for biological response modifiers
ATE335719T1 (de) Polyamine und ihre therapeutische verwendung
HU911929D0 (en) Process for the production of conjugates containing orto ligating functional group from chelate complexes and joint antibodies or antibody fragments and the medical preparations containing thereof
DK5188D0 (da) Antistof-folinsyreanalogkonjugat, dets fremstilling, samt ved fremstillingen anvendeligt mellemprodukt og fremstilling deraf
EP0579802A4 (en) Bicycle-polyazamacrocyclocarboxylic acid complexes, conjugates, preparation and use as contrast agents
CA2089853A1 (fr) Conjugues polyethyleneglycol-hirudine, leur procede de preparation et leur emploi pour le traitement des thromboses
TWI266801B (en) Polyol-IFN-beta conjugates
GB2226494B (en) Photosynthesis in men's blood to cure cancer-part 2 phmd(cancer)
AU3109095A (en) Conjugates of metal complexes and oligonucleotides, which specifically bond to specific target structures, agents containing these conjugates, their use in nmr diagnosis as well as process for their production
HK53791A (en) Po-man's photosynthesis in men's blood to cure cancer(phmdcc)
RU93053897A (ru) Комплексы бициклополиазамакроциклокарбоновых кислот, их конъюгаты, фармацевтическая композиция, способ диагностики, набор и способ получения

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees